Mexico · Delayed Price · Currency is MXN Corpovael Statistics
Total Valuation
Corpovael has a market cap or net worth of MXN 2.17 billion. The enterprise value is 4.51 billion.
| Market Cap | 2.17B |
| Enterprise Value | 4.51B |
Important Dates
The next estimated earnings date is Friday, October 23, 2026.
| Earnings Date | Oct 23, 2026 |
| Ex-Dividend Date | Aug 27, 2026 |
Share Statistics
Corpovael has 292.64 million shares outstanding. The number of shares has decreased by -2.44% in one year.
| Current Share Class | 292.64M |
| Shares Outstanding | 292.64M |
| Shares Change (YoY) | -2.44% |
| Shares Change (QoQ) | -2.35% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | 0.00% |
| Float | n/a |
Valuation Ratios
The trailing PE ratio is 5.27 and the forward PE ratio is 5.65.
| PE Ratio | 5.27 |
| Forward PE | 5.65 |
| PS Ratio | 0.39 |
| PB Ratio | 0.37 |
| P/TBV Ratio | 0.37 |
| P/FCF Ratio | 19.92 |
| P/OCF Ratio | 18.30 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 7.52, with an EV/FCF ratio of 41.47.
| EV / Earnings | 10.66 |
| EV / Sales | 0.81 |
| EV / EBITDA | 7.52 |
| EV / EBIT | 7.71 |
| EV / FCF | 41.47 |
Financial Position
The company has a current ratio of 2.37, with a Debt / Equity ratio of 0.46.
| Current Ratio | 2.37 |
| Quick Ratio | 0.72 |
| Debt / Equity | 0.46 |
| Debt / EBITDA | 5.10 |
| Debt / FCF | 25.05 |
| Interest Coverage | 6.26 |
Financial Efficiency
Return on equity (ROE) is 7.35% and return on invested capital (ROIC) is 5.40%.
| Return on Equity (ROE) | 7.35% |
| Return on Assets (ROA) | 2.50% |
| Return on Invested Capital (ROIC) | 5.40% |
| Return on Capital Employed (ROCE) | 5.06% |
| Weighted Average Cost of Capital (WACC) | 2.64% |
| Revenue Per Employee | 35.27M |
| Profits Per Employee | 2.69M |
| Employee Count | 157 |
| Asset Turnover | 0.43 |
| Inventory Turnover | 1.11 |
Taxes
In the past 12 months, Corpovael has paid 86.55 million in taxes.
| Income Tax | 86.55M |
| Effective Tax Rate | 16.98% |
Stock Price Statistics
The stock price has increased by +125.61% in the last 52 weeks. The beta is -0.27, so Corpovael's price volatility has been lower than the market average.
| Beta (5Y) | -0.27 |
| 52-Week Price Change | +125.61% |
| 50-Day Moving Average | 7.45 |
| 200-Day Moving Average | 5.97 |
| Relative Strength Index (RSI) | 49.61 |
| Average Volume (20 Days) | 2,308 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Corpovael had revenue of MXN 5.54 billion and earned 423.01 million in profits. Earnings per share was 1.40.
| Revenue | 5.54B |
| Gross Profit | 1.22B |
| Operating Income | 518.39M |
| Pretax Income | 509.80M |
| Net Income | 423.01M |
| EBITDA | 525.56M |
| EBIT | 518.39M |
| Earnings Per Share (EPS) | 1.40 |
Balance Sheet
The company has 435.06 million in cash and 2.72 billion in debt, with a net cash position of -2.29 billion or -7.82 per share.
| Cash & Cash Equivalents | 435.06M |
| Total Debt | 2.72B |
| Net Cash | -2.29B |
| Net Cash Per Share | -7.82 |
| Equity (Book Value) | 5.90B |
| Book Value Per Share | 19.98 |
| Working Capital | 3.87B |
Cash Flow
In the last 12 months, operating cash flow was 118.31 million and capital expenditures -9.60 million, giving a free cash flow of 108.71 million.
| Operating Cash Flow | 118.31M |
| Capital Expenditures | -9.60M |
| Depreciation & Amortization | 7.17M |
| Net Borrowing | 379.42M |
| Free Cash Flow | 108.71M |
| FCF Per Share | 0.37 |
Margins
Gross margin is 22.08%, with operating and profit margins of 9.36% and 7.64%.
| Gross Margin | 22.08% |
| Operating Margin | 9.36% |
| Pretax Margin | 9.21% |
| Profit Margin | 7.64% |
| EBITDA Margin | 9.49% |
| EBIT Margin | 9.36% |
| FCF Margin | 1.96% |
Dividends & Yields
This stock pays an annual dividend of 0.38, which amounts to a dividend yield of 5.14%.
| Dividend Per Share | 0.38 |
| Dividend Yield | 5.14% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | 2 |
| Payout Ratio | 13.14% |
| FCF Payout Ratio | 102.29% |
| Buyback Yield | 2.44% |
| Shareholder Yield | 7.58% |
| Earnings Yield | 19.53% |
| FCF Yield | 5.02% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for Corpovael is 8.50, which is 14.87% higher than the current price. The consensus rating is "Buy".
| Price Target | 8.50 |
| Price Target Difference | 14.87% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | 6.27% |
| EPS Growth Forecast (3Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Corpovael has an Altman Z-Score of 1.5 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.5 |
| Piotroski F-Score | 5 |